CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About CADTH What We Do Programs and Services CADTH Reimbursement Review Umeclidinium/vilanterol

Umeclidinium/vilanterol

Last Updated: February 26, 2014

Result type: Reports

Project Number: SR0371-000

Product Line: Reimbursement Review

Generic Name: Umeclidinium/vilanterol

Brand Name: Anoro Ellipta

Manufacturer: GlaxoSmithKline Inc.

Therapeutic Area: Chronic obstructive pulmonary disease

Indications: Chronic Obstructive Pulmonary Disease

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: January 15, 2015

Recommendation Type: List with criteria/condition

Umeclidinium/vilanterol

Files